SFFS
SRPT icon

Stonehage Fleming Financial Services’s Sarepta Therapeutics SRPT Stock Holding History

Stonehage Fleming Financial Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Hold
9,614
– – 0.01% 150
2026
Q1 		$209K Hold
9,614
– – 0.01% 149
2025
Q4 		$207K Hold
9,614
– – 0.01% 142
2025
Q3 		$185K Buy
+9,614
New +$171K 0.01% 139

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Stonehage Fleming Financial Services's SRPT Position: Q2 2026 in Review

Stonehage Fleming Financial Services held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 9,614 shares worth $173K. The position accounts for 0.01% of the portfolio, ranked #150.

Stonehage Fleming Financial Services first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $209K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Stonehage Fleming Financial Services held 9,614 shares of Sarepta Therapeutics worth $173K as of Q2 2026.
  • Stonehage Fleming Financial Services left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up 0.01% of Stonehage Fleming Financial Services's portfolio in Q2 2026, its #150 holding.
  • Stonehage Fleming Financial Services first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Stonehage Fleming Financial Services's Sarepta Therapeutics position peaked at $209K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Stonehage Fleming Financial Services's 13F filing for Q2 2026, filed 17 Aug 2026.